SCHEMBL13229581

SCHEMBL13229581

CNC(=O)c1c[nH]c2ccsc2c1=O

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.55
HTR3A P46098 1/20 0.55
ALDH1A1 P00352 2/20 0.41
TP53 P04637 2/20 0.41
RAB9A P51151 1/20 0.41
LMNA P02545 1/20 0.41
MAPK1 P28482 1/20 0.41
POLB P06746 3/20 0.39
KMT2A Q03164 1/20 0.39
NR1I2 O75469 1/20 0.39
AHR P35869 1/20 0.39
MAPK10 P53779 1/20 0.38
CFTR P13569 7/20 0.38
TDP1 Q9NUW8 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR2B P41595 1/20 0.37
MAPT P10636 2/20 0.36
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23937804 0.89 CYP3A4 (0.43) CYP3A4HTR3AALDH1A1TP53RAB9A
SCHEMBL13229697 0.83 CYP3A4 (0.49) CYP3A4HTR3AALDH1A1TP53RAB9A
SCHEMBL2793777 0.81 CYP3A4 (0.50) CYP3A4HTR3AALDH1A1KMT2AMAPT
SCHEMBL13229587 0.80 CFTR (0.63) CYP3A4HTR3AALDH1A1TP53RAB9A
SCHEMBL6479523 0.80 POLB (0.56) CYP3A4HTR3ARAB9APOLBKMT2A
SCHEMBL6708336 0.80 CYP3A4 (0.49) CYP3A4HTR3AALDH1A1RAB9AMAPK1
SCHEMBL13229620 0.79 CYP3A4 (0.47) CYP3A4HTR3AALDH1A1TP53RAB9A
SCHEMBL13229624 0.79 CFTR (0.48) CYP3A4HTR3AALDH1A1TP53LMNA
SCHEMBL13229591 0.78 CYP3A4 (0.49) CYP3A4HTR3AALDH1A1TP53RAB9A
SCHEMBL10472393 0.77 GABRA1 (0.52) CYP3A4HTR3AHTR2AHTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140235668-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VPI VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-21 US disclosed
US-20130231364-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-05 US disclosed
US-8399479-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-03-19 US disclosed
US-20100168158-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-07-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235668-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VPI CFTR, ABCB1, ABCC1 CYP3A4 3757/4885HTR3A 4289/4885ALDH1A1 4065/4885
US-20100168158-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, ABCB1, ABCC1 CYP3A4 3621/4885HTR3A 3751/4885ALDH1A1 3001/4885
US-20130231364-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, ABCB1, ABCC1 CYP3A4 3621/4885HTR3A 3751/4885ALDH1A1 3001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.